Skip to content

Tackling Pressure Ulcer Via Bee Venom Phonophoresis

Tackling Chronic Pressure Ulcer Via Bee Venom Phonophoresis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06374563
Acronym
ulcer
Enrollment
30
Registered
2024-04-18
Start date
2022-11-09
Completion date
2024-03-01
Last updated
2024-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bee Venom, Phonophoresis, Pressure Ulcers

Keywords

phonophoresis, bee venom

Brief summary

This study aimed to investigate the efficiency of topical Bee Venom gel versus phonophoresis of Bee Venom gel to accelerate healing of chronic pressure ulcer

Detailed description

In this study, the Bee Venom gel was prepared in a gel formula. Patients with chronic pressure ulcers were enrolled randomly into two different groups. Group 1 received a topical application of Bee Venom gel, 3 times per weeks. While group 2 received phonophoresis of Bee Venom gel using low frequency ultrasound, 3 times per week. The treatment lasted for 8 consecutive weeks. The Image J Software is used to measure the wound surface area before and after treatment.

Interventions

OTHERgroup 1 received topical Bee venom gel

Group 1 received a topical application of Bee Venom gel, 3 times per weeks. The wound dressing changed day after day and was cleaned every time with normal saline.

OTHERGroup 2: Phonophoresis of Bee Venom gel

group 2 received phonophoresis of Bee Venom gel using low frequency ultrasound, 3 times per weeks

Sponsors

Badr University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

\- Patients with stage II and III chronic neuropathic ulcers.

Exclusion criteria

* Patients with chronic cardiac, * Patients with renal, and * Patients with hepatic diseases and * Diabetic patients. Additionally, * Patients with immunosuppressive diseases, * Patients with HIV, and * Anemia Patients

Design outcomes

Primary

MeasureTime frameDescription
wound surface area wound surface areaBefore starting treatment and after 8 weeks of treatmentImageJ Software was used to measure the wound size
wound volumeBefore starting treatment and after 8 weeks of treatmentwound volume was measured through the volumetric measurement method using a syringe filled with saline

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026